Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALLR, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| PARP/Tankyrase Inhibitor 2X-121 | Advanced Ovarian Cancer | Phase 2 · NCT03878849 | Recruiting |
| Fas Receptor Agonist APO010 | Relapsed/Refractory Multiple Myeloma | Phase 1/2 · NCT03196947 | Terminated |
| Irofulven | Metastatic Castration-Resistant Prostate Cancer Pa | Phase 2 · NCT03643107 | Completed |
| LiPlaCis | Phase 1: Advanced or Refractory Solid Tumours | Phase 1/2 · NCT01861496 | Completed |
| PARP inhibitor 2X-121 | Metastatic Breast Cancer | Phase 2 · NCT03562832 | Completed |
Also used in these trials (approved or third-party drugs, not ALLR's own candidates): Ixabepilone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALLR holds $17M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 14.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 43 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALLR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Thomas Jensen CEO |
Insider | 596,734 | 3.75% | 2026-01-28 |
| Jeremy R. Graff President and Chief Development Officer · +223,430 options |
Insider | 381,644 | 2.40% | 2026-01-28 |
| Jeffrey S Ervin CFO |
Insider | 150,000 | 0.94% | 2026-01-28 |
| Alexander Epshinsky CFO |
Insider | 85,051 | 0.53% | 2025-01-22 |
| Gerald W. McLaughlin Director · +50,000 options |
Insider | 70,000 | 0.44% | 2026-01-28 |
| Jesper Hoeiland Director |
Insider | 25,000 | 0.16% | 2026-01-28 |
Share count 15,910,724 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALLR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →